Search results
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 5 days agoEngitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human ...
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
Zacks via Yahoo Finance· 6 days agoThis new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody...
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Motley Fool via Yahoo Finance· 7 days agoFood and Drug Administration along those lines. But that's not all. Novavax is granting an exclusive...
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
Digital Journal· 5 days agoIt is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting ...
Stanford Startup to Tackle Drink Tampering with Nostalgia
WTNH-TV New Haven· 5 days agoJinx Drinx, a pioneering pouch-based alcohol brand, announces its official Las Vegas Nevada launch, offering consumers amazing taste with a fresh perspective on responsible consumption. A new ...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for...
FOX 4 Kansas City· 4 days agoEupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a...
Entrada Therapeutics CEO sells shares worth over $45,000 By Investing.com
Investing.com· 5 days agoIn a recent move, the CEO of Entrada Therapeutics, Inc. (NASDAQ:TRDA), Dipal Doshi, has sold a...
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
Zacks· 6 days agoThis new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks· 4 days agoThe subcutaneous formulation of Opdivo is co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20). The BLA seeks approval of the same across all ...
This Stock Just More Than Doubled in 1 Day: Is It a Buy? | The Motley Fool
The Motley Fool· 7 days agoThe biotech has come a long way since its not-so-successful attempt at dominating the coronavirus...